WHO ICTRP trial
Augmentation therapy comparison in refractory obsessive-compulsive disorder with…
IRCT2015110424882N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT2015110424882N1 |
|---|---|
| Public title | Augmentation therapy comparison in refractory obsessive-compulsive disorder with Aripiprazole vs. Risperidone |
| Scientific title | A survey about comparison of augmentation therapy in refractory obsessive-compulsive disorder patients; Aripiprazole vs. Risperidone |
| Primary sponsor | Kashan University of Medical Sciences, Dr Gholamali Hamidi |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Countries | Iran (Islamic Republic of) |
| Conditions | Obsessive-compulsive disorder. Obsessive-compulsive disorder;Obsessive-compulsive disorder |
| Interventions | Intervention 1: In a group of patients in addition to SSRI drugs, Aripiprazole, production of sobhan corporation, begun with 2.5 mg and increased gradually to 10 mg, at the end of second week. All of patients were visited 8 times by… |
| Registration date | Aug 4, 2016 |
| Target size | 100 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: